Annual report pursuant to Section 13 and 15(d)

Summary of Significant Accounting Policies and Estimates (Details 2)

v3.6.0.2
Summary of Significant Accounting Policies and Estimates (Details 2) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2015
Sep. 30, 2015
Jun. 30, 2015
Mar. 31, 2015
Dec. 31, 2016
 [1]
Dec. 31, 2015
Dec. 31, 2014
Numerator:                      
Net loss applicable to common stockholders $ (5,576) $ (11,494) $ (9,970) $ (6,775) $ (9,300) $ (5,185) $ (5,645) $ (4,115) $ (33,815) $ (24,245) $ (33,769)
Adjustment for gain on fair value of warrant liability                 (4,286) (2,505) 0
Adjusted net loss used for dilution calculation                 $ (38,101) $ (26,750) $ (33,769)
Denominator                      
Weighted-average number of shares outstanding                 18,126 14,606 11,181
Effect of potential dilutive shares                 496 3 0
Dilutive weighted-average number of shares outstanding                 18,622 14,609 11,181
Net loss per share applicable to common stockholders                      
Basic (in dollars per share) $ (0.29) [2] $ (0.60) [2] $ (0.61) [2] $ (0.44) [2]         $ (1.87) $ (1.66) $ (3.02)
Diluted (in dollars per share) $ (0.35) [2] $ (0.60) [2] $ (0.61) [2] $ (0.44) [2]         $ (2.05) $ (1.83) $ (3.02)
[1] Recognition of previously deferred revenue and cost of goods in the year ended December 31, 2016 reduced net loss applicable to common stockholders by $2,358, or $0.13 per share (see Note 2. Basis of Presentation and Summary of Significant Accounting Policies and Estimates – Medical Device Revenue and Cost of Revenue Recognition).
[2] Quarterly net loss per common share amounts may not total to the annual amounts due to rounding and the changes in the number of weighted common shares outstanding and included in the calculation of basic and diluted common shares.